DIARECT AG of Freiburg at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine
Manufacturers

DIARECT AG

Bötzinger Str. 29B, 79111 Freiburg
Germany
Telephone +49 761 47979-0
Fax +49 761 47979-29
info@diarect.com

This company is main exhibitor of

Hall map

MEDICA 2018 hall map (Hall 3A): stand 3AD27

Fairground map

MEDICA 2018 fairground map: Hall 3A

Contact

Dr. Katharina Bonfig

Head Sales and Marketing

Phone
+49 761 47979-0

Email
info@diarect.com

Our range of products

Product categories

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.05  Other equipment for clinical chemistry

Other equipment for clinical chemistry

  • 03  Diagnostics
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.01  Immuno assay testing

Immuno assay testing

  • 03  Diagnostics
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.04  Other equipment for immunochemistry and immunology

Other equipment for immunochemistry and immunology

  • 03  Diagnostics
  • 03.05  Infectious immunology testing
  • 03.05.02  Microbiological diagnosis, virology, equipment and systems for

Microbiological diagnosis, virology, equipment and systems for

Our products

Product category: Immuno assay testing

Presenting DIARECT's Products

We are excited to introduce our new products, highlighting our most recent innovations in autoimmunity, allergy and infectious disease serology.

More Less

Company news

Date

Topic

Download

Nov 9, 2018

Completing the Anaplasma portfolio: Anaplasma phagocytophilum OmpA

Human Granulocytic Anaplasmosis (HGA) was first recognized in the United States and is the most common tick-borne disease after Borreliosis. It is endemic in 42 countries with an overall case fatality of 5%. The causative agent of HGA is the rickettsial species Anaplasma phagocytophilum, a Gram-negative obligate intracellular pathogen infecting mammalian hosts worldwide. It invades and replicates within neutrophils by employing an array of mechanisms to subvert their bactericidal activity. Characteristic is the development of intracytoplasmic morulae within those peripheral blood granulocytes. Several epitopes on surface proteins of Anaplasma phagocytophilum are targeted during an immune response.

Major outer membrane protein A (OmpA) of A. phagocytophilum is a peptidoglycan-binding lipoprotein, transcriptionally upregulated during tick transmission feeding and playing an important role in the pathogenesis of HGA. The integral outer membrane channel belongs to the porin superfamily, which share a beta-barrel structure.

The invasion domain of OmpA is conserved in all Anaplasma and Ehrlichia species. Invasion is mediated by interaction of the protein with α2,3-sialic acid of the sialyl Lewis x (sLex) tetrasaccharide, which caps P-selectin glycoprotein ligand-1 (PSGL-1) and other glycoproteins on eukaryotic cell surfaces. Binding of the bacterium to these receptors on the membrane promotes endocytosis. Therefore, the invasin OmpA, together with other proteins, is important for entry into mammalian cells and critical for infection of neutrophils in host cells. Using an agonist for OmpA receptors, e.g. glutathione S-transferase (GST)–OmpA, shows that A. phagocytophilum infection of host cells is reduced by approximately 50 % as it blocks access of native OmpA on the bacterial surface to sialic acids.

Until now, DIARECT has provided the immunodominant major surface protein 5 (Msp5), also present in the salivary glands of infected ticks, and A. phagocytophilum p44, a transmembrane protein of the outer membrane, which is thought to enable the bacterium to avoid host immune surveillance. To complete the Anaplasma product line, DIARECT is now offering a third A. phagocytophilum antigen produced in E. coli to expand this product line: OmpA. All three proteins are considered main antigens of antibody response to HGA.

References:
Atifi et al. (2015) Parasitol Res. DOI 10.1007/s00436-015-4698-2
Blanco and Oteo (2002) Clin Microbiol and Infect. 8: 763–772
Chen et al. (1994) J Clin Microbiol. 32:589–595
Ijdo et al. (1998) Infect Immun. 66: 3264–3269
Kahlon et al. (2013) Infect Immun. 81:65-79
Knowles et al. (1996) J Clin Microbiol. 34: 2225-2230
Lotric-Furlan et al. (1998) Clin Infect Dis. 27: 424–428
Ojogun et al. (2012) Infect Immun. 80: 3748–3760
Palmer et al. (1994) J Clin Microbiol. 42:5381–5384
Park et al. (2003) Infect Immun. 71: 4018–4025
Rikihisa et al. (2007) Journal Bacteriol. 189: 7819–7828
Wang et al. (2013) PLoS One. 8 (10): e78189

For additional product related information please feel free to contact us at:
Tel: +49 761 47979-0
Email: info@diarect.com

More Less

Nov 9, 2018

Recombinant Shrimp Allergen: Pen a 1

Penaeus aztecus (brown shrimp), also known as Farfantepenaeus aztecus, is closely related to the most imported species of farmed crustaceans worldwide, the giant tiger prawn (P. monodon). Despite the fact that shrimp-based food is a significant source of cholesterol, it is considered healthy for the cardiovascular system, due to the low levels of saturated fat. The high cholesterol content in shrimp improves the ratio of LDL to HDL cholesterol and lowers triglycerides. Moreover, shrimp is high in calcium, iodine, protein and omega-3s. However, hypersensitivity to crustacean food is relatively common and clinical manifestations following ingestion can be severe, including local and systemic reactions, which can lead, in the most severe cases, to life-threatening anaphylaxis.

The use of recombinant proteins in allergy diagnostics has several advantages over crude allergen extracts including more precise quantification of the immunologically active substance. Extracts that are prepared from natural sources may contain mixtures of several proteins including non-allergens, and can vary from batch to batch. Recombinant allergens are therefore the ideal basis to improve component resolved diagnostics (CRD) since large quantities with high purity and standardized quality can be produced.

Although a large number of crustacean and mollusk species have been studied, only a few IgE-binding proteins have been identified. In the majority of these studies the identified allergen component is tropomyosin and its isoform variants in other invertebrates. The protein, considered to be the only major allergen in shrimp, is a highly conserved and soluble muscle protein characterized by an alpha-helical homodimeric, coiled-coil structure. It plays a functional role in contractile activities of cells and is therefore important in the regulation of cell morphology and motility. Immunological relationship due to IgE cross-reactivites among crustaceans and the high degree of homologous regions within this protein family suggest that tropomyosin is an important cross-sensitizing pan allergen.

Tropomyosin of P. aztecus (34 - 38 kDa), designated Pen a 1, is representative of shrimp tropomyosin, used in the investigation of food allergies in which tropomyosin is a major determinant. From the thirteen different allergens identified in brown shrimp, it is the best characterized, been detected in sera of more than 80% of shrimp allergic subjects, and binds to 75% of the shrimp-specific IgE.

DIARECT’s recombinant Pen a 1 has close biochemical and immunological similarity to purified natural tropomyosin and is produced in the baculovirus/insect cell expression system.

References:
Atifi et al. (2015) Parasitol Res. DOI 10.1007/s00436-015-4698-2
Castillo et al. (1994) Allergol Immunopathol. 22: 83–87
Daul et al. (1991) J Allergy Clin Immunol. 87:192
Daul et al. (1993) CRC press. 291-294
Daul et al. (1994) Int Arch Allergy Immunol.105:49-55
DeWitt et al. (2004) Mol Nutr Food Res. 48: 370– 379
Jeoung et al. (1997) J Allergy Clin Immunol. 229–234
Lehrer et al. (1987) J Allergy Clin Immunol. 80: 133 –139
Reese et al. (1999) Int Arch Aller Immunol. 119: 247-258
Sadek et al. (2018) BioInvasions Rec. 7: 51–54
Shanti et al. (1993) J Allergy Clin Immunol. 151: 5354-5363
Silva et al. (1996) Am J Clin Nutr. 64:712–717
Waring et al. (1985) J Allergy Clin Immunol. 76: 440–445
Wang et al. (2013) PLoS One. 8 (10): e78189

For questions or additional information please feel free to contact us at:
Tel: +49 761 47979-0
Email: info@diarect.com

More Less

Nov 9, 2018

New Human Chimeric Monoclonal Antibodies: PL-7 humAb IgG, PL-12 humAb IgG and Sp100 humAb IgG

For mRNA translation at the ribosomes, amino acids are covalently attached (“loaded”) onto their respective tRNAs by specific aminoacyl-tRNA synthetases. Threonyl-tRNA synthetase (PL-7) is specific for the amino acid threonine and Alanyl-tRNA synthetase (PL-12) is specific for the amino acid alanine.

PL-7 and PL-12 autoantibodies are considered important serological markers in dermatomyositis, an idiopathic myopathy characterized by the presence of inflammatory infiltrates within skeletal muscle. Together with polymyositis, dermatomyositis is one of the most common subtypes of these idiopathic myopathies along with inclusion body myositis, childhood myositis, malignancy-associated myositis, and myositis in overlap with mixed connective tissue disease. To date, autoantibodies targeting eight of the 20 aminoacyl-tRNA synthetases have been identified, being found in up to 30% of sera from patients with myositis. They are highly specific for this disorder and strongly associated with complicating lung disease.

Sp100 is a nuclear protein with a deduced molecular weight of 55 kDa that is named after its speckled/multinuclear dots pattern (MND-ANA) in IIF and aberrant mobility at 100 kDa in protein gels. The cellular function of Sp100 is not well understood, but it appears to be involved in the regulation of gene transcription and the cellular response to viral infections. Primary Biliary Cirrhosis (PBC) is a chronic and progressive autoimmune liver disease, which is characterized by the destruction of bile ducts and portal inflammation leading to liver cirrhosis and consequently to hepatic failure. Autoantibodies are directed against Sp100, found in approximately 25% of PBC patients and are considered a highly specific marker in the diagnosis of this disease.

Technological breakthroughs and innovative technologies continue to shape the in vitro diagnostic field. One of these advances in assay development are chimeric monoclonal antibodies for use as positive controls or calibrators in IVD kits as an alternative to characterized disease state plasma, which are limited in availability, show variability, and have safety and ethical issues.

These chimeric monoclonal antibodies are produced in transgenic mouse strains in which the sequence for mouse IgG1 Fc region is substituted with the human sequence. After mouse immunization and hybridoma technology, antibodies are generated that retain a human constant region required for recognition by the anti-human conjugate. These monoclonal antibodies can then be produced using standard cell culture technologies.

DIARECT has been continually expanding the line of tissue-specific chimeric antibodies for the detection and diagnosis of autoimmune liver diseases, and with these new products, we have completed our portfolio of myositis antibodies.

References:
Betteridge et al. (2011) Arthritis Research & Therapy. 13:209-215
Cogné et al. (2013) European Patent N°13305964.2
Gunawardena et al. (2015) Clinic Rev Allerg Immunol. DOI 10.1007/s12016-015-8513-8
Invernizzi et al. (2008) World J Gastroenterol. 21:3374-3387
Mathews et al. (1984) J Exp Med. 160:420-434
Oertelt et al. (2007) Hepatology. 45 (3): 659-665
Yamasaki et al. (2006) Arthritis & Rheumatism. 54: 2004–2009
Zhang et al. (2014) Hepatology. 60: 1708–1716
Sherer et al. (2004) Semin Arthritis Rheum. 34:501-537

For questions or additional information please feel free to contact us at:
Tel: +49 761 47979-0
Email: info@diarect.com

More Less

About us

Company details

About DIARECT

Privately owned DIARECT AG was established in Freiburg in 1998.   Our area of expertise lies in the development, large-scale production and worldwide distribution of recombinant and native antigens for autoimmune diagnostics. Additionally, our product portfolio includes antigens for allergy diagnostics and infectious serology, mainly focused on tick-borne diseases. The newest product line, biotinylated antigens includes several recombinant and non-recombinant autoimmune antigens. Providing our customers with products and services of constantly high quality, to improve the life of patients worldwide is our philosophy. Therefore, we have implemented Quality Management Systems that are certified for compliance with ISO 9001 and 13485 standards.

Our antigens undergo a rigorous series of tests in our quality control lab. Each lot is subjected to various biochemical and immunological analyses to assure conformance to strict product specifications. This guarantees consistent results, reduces assay development time and increases the productivity of our customers. Product and customer specific service is our trademark to improve and help you finding the best way to improve your assay development and/or research application.

For questions or additional information please feel free to contact us at:

Tel: +49 761 47979-0
Email: info@diarect.com

More Less